This substrate sequence information was then used to develop a peptoid-based inhibitor that initiates cell death in both MDA468 and HCT116 cancer cells, which suggests PRMT1 as a viable therapeutic target and thus the development of more potent inhibitors is therefore warranted [24,25]. The gene discussed is PRMT1; the disease is cancer.